Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 7
Submit an article Journal homepage
328
Views
3
CrossRef citations to date
0
Altmetric
Letter to the Editor

Ibrutinib as salvage therapy in mantle cell lymphoma with central nervous system involvement in a pretreated unfit patient

Orsola VitaglianoDepartment of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy; Correspondence[email protected]
,
Fabio TrastulliDepartment of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy;
,
Fabiana CacaceDepartment of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy;
,
Stefania LeoneDepartment of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy;
,
Mara MemoliDepartment of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy;
,
Giulia ScaliaClinical and Experimental Cytometry Unit, CEINGE – Biotecnologie Avanzate, Napoli, Italy;
,
Marianna NotarangeloDepartment of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy;
,
Ciro G. MainolfiAdvanced Biomedical Sciences, University of Naples ‘Federico II’, Napoli, Italy
,
Amalia De RenzoDepartment of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy;
&
Fabrizio PaneDepartment of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy;
show all
Pages 1734-1737 | Received 01 May 2017, Accepted 26 Sep 2017, Published online: 11 Oct 2017

References

  • Cheah CY, Seymour JF, Wang ML. Mantle cell lymphoma. J Clin Oncol. 2016;34:1256–1269.
  • Argatoff LH, Connors JM, Klasa RJ, et al. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood. 1997;89:2067–2078.
  • Bedotto J, Spier CM, Paquin ML, et al. Mantle zone lymphoma with central nervous system involvement. Cancer. 1986;58:2125–2129.
  • Ellison DJ, Turner RR, Van AR, et al. High-grade mantle zone lymphoma. Cancer. 1987;60:2717–2720.
  • Cheah CY, George A, Giné E, et al. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma. Ann Oncol. 2013;24:2119–2123.
  • Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;23:7013–7023.
  • Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005;23:1984–1992.
  • Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:3383–3389.
  • Campo E, Rule S. Mantle cell lymphoma: evolving management strategies. Blood. 2015;125:48–55.
  • Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.
  • Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–516.
  • Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126:739–745.
  • Mason C, Savona S, Rini JN, et al. Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome [letter]. Br J Haematol. 2016 [July 13]. doi: 10.1111/bjh.14218
  • Bernard S, Goldwirt L, Amorim S, et al. Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse. Blood. 2015;126:1695–1698.
  • Tucker DL, Naylor G, Kruger A, et al. Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement – a multi-centre case series from the United Kingdom. Br J Haematol. 2017;178:327–329.
  • Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387:770–778.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.